SGCA

(redirected from LGMD2D)
Also found in: Acronyms.

SGCA

A gene on chromosome 17q21 that encodes a component of the dystrophin-glycoprotein complex, which is thought to be restricted to striated muscle. It stabilises muscle cell membranes and links the actin cytoskeleton to the extracellular matrix.

Molecular pathology
SGCA mutations result in type 2D autosomal recessive limb-girdle muscular dystrophy.
References in periodicals archive ?
LGMD2D is believed to be the most common sarcoglycanopathy, with conservative estimates indicating it affects approximately three per m people, regardless of gender, race, or ethnicity.
Myonexus Therapeutics' pipeline includes three clinical stage gene therapy programs (LGMD2E, LGMD2D, and LGMD2B) and two preclinical gene therapy programs (LGMD2C and LGMD2L).
The company's pipeline includes three clinical stage gene therapy programmes (LGMD2E, LGMD2D, and LGMD2B) and two preclinical gene therapy programmes (LGMD2C and LGMD2LO).